Search

Your search keyword '"Szymonifka, Jackie"' showing total 280 results
Start Over Author "Szymonifka, Jackie" Publication Type Academic Journals
280 results on '"Szymonifka, Jackie"'

2. Validation of the Hip Disability and Osteoarthritis Outcome Score and Knee Injury and Osteoarthritis Outcome Score Pain and Function Subscales for Use in Total Hip Replacement and Total Knee Replacement Clinical Trials

Author

Goodman, Susan M., Mehta, Bella Y., Mandl, Lisa A., Szymonifka, Jackie D., Finik, Jackie, Figgie, Mark P., Navarro-Millán, Iris Y., Bostrom, Mathias P., Parks, Michael L., Padgett, Douglas E., McLawhorn, Alexander S., Antao, Vinicius C., Yates, Adolph J., Springer, Bryan D., Lyman, Stephen L., and Singh, Jasvinder A.

Published
2020
Full Text
View/download PDF

4. Coronary sinus biomarker sampling compared to peripheral venous blood for predicting outcomes in patients with severe heart failure undergoing cardiac resynchronization therapy: The BIOCRT study

Author

Truong, Quynh A, Januzzi, James L, Szymonifka, Jackie, Thai, Wai-ee, Wai, Bryan, Lavender, Zachary, Sharma, Umesh, Sandoval, Ryan M, Grunau, Zachary S, Basnet, Sandeep, Babatunde, Adefolakemi, Ajijola, Olujimi A, Min, James K, and Singh, Jagmeet P

Subjects
Clinical Research, Cardiovascular, Heart Disease, Detection, screening and diagnosis, 4.1 Discovery and preclinical testing of markers and technologies, 4.2 Evaluation of markers and technologies, Aged, Aged, 80 and over, Biomarkers, Blood Specimen Collection, Cardiac Resynchronization Therapy, Coronary Sinus, Female, Follow-Up Studies, Galectin 3, Heart Failure, Humans, Male, Middle Aged, Natriuretic Peptide, Brain, Peptide Fragments, Predictive Value of Tests, Prospective Studies, Risk Assessment, Severity of Illness Index, Survival Rate, Treatment Outcome, Veins, Biomarker, Coronary sinus, Galectin-3, Soluble 512, Cardiac resynchronization therapy, Soluble ST2, Biomedical Engineering, Cardiorespiratory Medicine and Haematology, Cardiovascular System & Hematology
Abstract

BackgroundA significant minority of patients receiving cardiac resynchronization therapy (CRT) remain nonresponsive to this intervention.ObjectiveThis study aimed to determine whether coronary sinus (CS) or baseline peripheral venous (PV) levels of established and emerging heart failure (HF) biomarkers are predictive of CRT outcomes.MethodsIn 73 patients (aged 68 ± 12 years; 83% men; ejection fraction 27% ± 7%) with CS and PV blood samples drawn simultaneously at the time of CRT device implantation, we measured amino-terminal pro-B-type natriuretic peptide (NT-proBNP), galectin-3 (gal-3), and soluble ST2 (sST2) levels. NT-proBNP concentrations >2000 pg/mL, gal-3 concentrations >25.9 ng/mL, and sST2 concentrations >35 ng/mL were considered positive on the basis of established PV cut points for identifying "high-risk" individuals with HF. CRT response was adjudicated by the HF Clinical Composite Score. A major adverse cardiovascular event (MACE) was defined as the composite end point of death, cardiac transplant, left ventricular assist device, and HF hospitalization at 2 years.ResultsNT-proBNP concentrations were 20% higher in the CS than in the periphery, while gal-3 and sST2 concentrations were 10% higher in the periphery than in the CS (all P < .001). There were 45% CRT nonresponders at 6 months and 16 (22%) patients with MACE. Triple-positive CS values yielded the highest specificity of 95% for predicting CRT nonresponse. Consistently, CS strategies identified patients at higher risk of developing MACE, with >11-fold adjusted increase for triple-positive CS patients compared to triple-negative patients (all P ≤ .04). PV strategies were not predictive of MACE.ConclusionOur findings suggest that CS sampling of HF biomarkers may be better than PV sampling for predicting CRT outcomes. Larger studies are needed to confirm our findings.

Published
2014

43. Spatial environmental factors predict cardiovascular and all-cause mortality: Results of the SPACE study.

Author

Hadley, Michael B., Nalini, Mahdi, Adhikari, Samrachana, Szymonifka, Jackie, Etemadi, Arash, Kamangar, Farin, Khoshnia, Masoud, McChane, Tyler, Pourshams, Akram, Poustchi, Hossein, Sepanlou, Sadaf G., Abnet, Christian, Freedman, Neal D., Boffetta, Paolo, Malekzadeh, Reza, and Vedanthan, Rajesh

Subjects
MORTALITY, INDOOR air pollution, AIR pollution, SOLAR chimneys, PERCUTANEOUS coronary intervention, KEROSENE as fuel, PARTICULATE matter
Abstract

Background: Environmental exposures account for a growing proportion of global mortality. Large cohort studies are needed to characterize the independent impact of environmental exposures on mortality in low-income settings. Methods: We collected data on individual and environmental risk factors for a multiethnic cohort of 50,045 individuals in a low-income region in Iran. Environmental risk factors included: ambient fine particular matter air pollution; household fuel use and ventilation; proximity to traffic; distance to percutaneous coronary intervention (PCI) center; socioeconomic environment; population density; local land use; and nighttime light exposure. We developed a spatial survival model to estimate the independent associations between these environmental exposures and all-cause and cardiovascular mortality. Findings: Several environmental factors demonstrated associations with mortality after adjusting for individual risk factors. Ambient fine particulate matter air pollution predicted all-cause mortality (per μg/m3, HR 1.20, 95% CI 1.07, 1.36) and cardiovascular mortality (HR 1.17, 95% CI 0.98, 1.39). Biomass fuel use without chimney predicted all-cause mortality (reference = gas, HR 1.23, 95% CI 0.99, 1.53) and cardiovascular mortality (HR 1.36, 95% CI 0.99, 1.87). Kerosene fuel use without chimney predicted all-cause mortality (reference = gas, HR 1.09, 95% CI 0.97, 1.23) and cardiovascular mortality (HR 1.19, 95% CI 1.01, 1.41). Distance to PCI center predicted all-cause mortality (per 10km, HR 1.01, 95% CI 1.004, 1.022) and cardiovascular mortality (HR 1.02, 95% CI 1.004, 1.031). Additionally, proximity to traffic predicted all-cause mortality (HR 1.13, 95% CI 1.01, 1.27). In a separate validation cohort, the multivariable model effectively predicted both all-cause mortality (AUC 0.76) and cardiovascular mortality (AUC 0.81). Population attributable fractions demonstrated a high mortality burden attributable to environmental exposures. Interpretation: Several environmental factors predicted cardiovascular and all-cause mortality, independent of each other and of individual risk factors. Mortality attributable to environmental factors represents a critical opportunity for targeted policies and programs. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

45. Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker

Author

Sgroi, Dennis C., Carney, Erin, Zarrella, Elizabeth, Steffel, Lauren, Binns, Shemeica N., Finkelstein, Dianne M., Szymonifka, Jackie, Bhan, Atul K., Shepherd, Lois E., Zhang, Yi, Schnabel, Catherine A., Erlander, Mark G., Ingle, James N., Porter, Peggy, Muss, Hyman B., Pritchard, Katherine I., Tu, Dongsheng, Rimm, David L., and Goss, Paul E.

Published
2013
Full Text
View/download PDF

47. Hospital readmission in systemic sclerosis associated pulmonary hypertension: Results from the PHAROS registry.

Author

Showalter, Kimberly, Pinheiro, Laura C, Jannat-Khah, Deanna, Sobol, Irina, Szymonifka, Jackie, Finik, Jackie, Steen, Virginia D, and Gordon, Jessica K

Subjects
PULMONARY hypertension treatment, REPORTING of diseases, KRUSKAL-Wallis Test, CONFIDENCE intervals, PULMONARY hypertension, HOME care services, SYSTEMIC scleroderma, PATIENT readmissions, FISHER exact test, MANN Whitney U Test, RISK assessment, SEVERITY of illness index, COMPARATIVE studies, DESCRIPTIVE statistics, OXYGEN therapy, LOGISTIC regression analysis, ODDS ratio, DISEASE complications
Abstract

Objective To identify individual-level factors associated with hospital readmission among individuals with SSc-associated pulmonary hypertension (SSc-PH). Methods Individuals enrolled in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) registry contributed clinical data related to SSc-PH disease severity and hospital admissions. Readmission was defined as a subsequent hospitalization within 12 months of any hospital discharge. Characteristics were compared between individuals with and without readmissions using Fisher's exact test, Wilcoxon rank-sum test, or Kruskal–Wallis test. Logistic regression was used to estimate associations between clinical predictors and likelihood of readmission. Results Of 572 individuals with SSc-PH enrolled in PHAROS, 54% had ≥1 hospitalizations between 2005 and 2016. Among individuals ever-hospitalized, 34% had ≥1 readmission. Individuals with vs without readmissions had shorter median (IQR) time between index hospitalization date and next PHAROS visit [37 (3, 80) vs 81 (42, 136) days, P <0.001]. Index admissions related to PH or SSc (vs non-PH/SSc related) were associated with an increased odds of 12-month readmission [aOR 6.6 (95% CI 3.2, 13.6) and aOR 2.2 (95% CI 1.1, 4.5), respectively]. Readmission was less likely among home oxygen users (vs non-users) (aOR 0.44; 95% CI 0.22, 0.89). Race, age, sex, disease duration and disease subtype were not associated with readmission. Conclusion The strongest predictor for 12-month readmission was an index hospitalization reason related to PH. Home oxygen use was associated with lower odds of readmission. Future studies should determine whether testing for the need for home oxygen mediates the risk of readmission in SSc-PH. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results